- The use of non-steroidal anti-inflammatory drugs (NSAIDs) was associated with a decreased risk for Alzheimer disease (AD) mortality in older adults.
Why this matters
- Findings support the hypothesis that the use of NSAIDs is a protective factor of developing AD.
- This population-based study included 5072 participants without AD (age, ≥65 years) who were followed for a median of 12.7 years.
- Sociodemographic, comorbidity factors, and current medications were recorded at baseline.
- Funding: Fondo Europeo de Desarrollo Regional and Sanidad de Castilla y Leo´n.
- Of 5072 participants, 2672 (52.7%) died over a median follow-up of 6.8 (range, 0.01-13.8) years, including 504 (18.9%) NSAIDs users and 2168 (81.1%) non-users.
- Of 2672 deceased participants, 113 died because of AD (8 [1.6%] among NSAIDs users and 105 [4.8%] in non-users; chi-square, 10.70; P=.001).
- In an unadjusted Cox model, NSAIDs users vs non-users were at a lower risk for AD mortality (HR, 0.35; 95% CI, 0.17-0.72; P=.004).
- After adjusting for confounders:
- The risk for AD mortality was lower in NSAIDs users vs non-users (HR, 0.29; 95% CI, 0.12-0.73; P=.009).
- Aspirin NSAIDs significantly reduced the risk for AD mortality (HR, 0.28; 95% CI, 0.10-0.90; P=.033).
- Risk for AD mortality decreased with non-aspirin NSAIDs but did not reach statistical significance (HR, 0.25; 95% CI, 0.10-1.03; P=.056).
- Study did not consider the dose and frequency of NSAIDs.
- Data on NSAIDs exposure for any intermediate time intervals between baseline and follow-up were not included.